222 related articles for article (PubMed ID: 10916757)
21. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.
Mazor R; Zhang J; Xiang L; Addissie S; Awuah P; Beers R; Hassan R; Pastan I
Mol Cancer Ther; 2015 Dec; 14(12):2789-96. PubMed ID: 26443804
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin.
Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3358-62. PubMed ID: 2014255
[TBL] [Abstract][Full Text] [Related]
23. An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin.
Debinski W; Pastan I
Bioconjug Chem; 1994; 5(1):40-6. PubMed ID: 8199233
[TBL] [Abstract][Full Text] [Related]
24. Localization of mesothelin in epithelial ovarian cancer.
Hassan R; Kreitman RJ; Pastan I; Willingham MC
Appl Immunohistochem Mol Morphol; 2005 Sep; 13(3):243-7. PubMed ID: 16082249
[TBL] [Abstract][Full Text] [Related]
25. Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers.
Brinkmann U; Webber K; Di Carlo A; Beers R; Chowdhury P; Chang K; Chaudhary V; Gallo M; Pastan I
Int J Cancer; 1997 May; 71(4):638-44. PubMed ID: 9178820
[TBL] [Abstract][Full Text] [Related]
26. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
Kreitman RJ; Hansen HJ; Jones AL; FitzGerald DJ; Goldenberg DM; Pastan I
Cancer Res; 1993 Feb; 53(4):819-25. PubMed ID: 8428363
[TBL] [Abstract][Full Text] [Related]
27. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer.
FitzGerald DJ; Willingham MC; Pastan I
Proc Natl Acad Sci U S A; 1986 Sep; 83(17):6627-30. PubMed ID: 3018739
[TBL] [Abstract][Full Text] [Related]
29. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.
Schmidt M; McWatters A; White RA; Groner B; Wels W; Fan Z; Bast RC
Gynecol Oncol; 2001 Feb; 80(2):145-55. PubMed ID: 11161852
[TBL] [Abstract][Full Text] [Related]
30. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer.
Pai LH; Bookman MA; Ozols RF; Young RC; Smith JW; Longo DL; Gould B; Frankel A; McClay EF; Howell S
J Clin Oncol; 1991 Dec; 9(12):2095-103. PubMed ID: 1960550
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
Hassan R; Schweizer C; Lu KF; Schuler B; Remaley AT; Weil SC; Pastan I
Lung Cancer; 2010 Jun; 68(3):455-9. PubMed ID: 19744744
[TBL] [Abstract][Full Text] [Related]
32. Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model.
Willingham MC; FitzGerald DJ; Pastan I
Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2474-8. PubMed ID: 3104916
[TBL] [Abstract][Full Text] [Related]
33. Characterization of immunotoxins active against ovarian cancer cell lines.
Pirker R; FitzGerald DJ; Hamilton TC; Ozols RF; Laird W; Frankel AE; Willingham MC; Pastan I
J Clin Invest; 1985 Sep; 76(3):1261-7. PubMed ID: 3930572
[TBL] [Abstract][Full Text] [Related]
34. Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with
Nguyen MQ; Kim DH; Shim HJ; Ta HKK; Vu TL; Nguyen TKO; Lim JC; Choe H
Mol Cells; 2023 Dec; 46(12):764-777. PubMed ID: 38052492
[TBL] [Abstract][Full Text] [Related]
35. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.
Brinkmann U; Pai LH; FitzGerald DJ; Willingham M; Pastan I
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8616-20. PubMed ID: 1924323
[TBL] [Abstract][Full Text] [Related]
36. Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme.
Hjortland GO; Garman-Vik SS; Juell S; Olsen OE; Hirschberg H; Fodstad O; Engebraaten O
J Neurosurg; 2004 Feb; 100(2):320-7. PubMed ID: 15086240
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.
Bauss F; Lechmann M; Krippendorff BF; Staack R; Herting F; Festag M; Imhof-Jung S; Hesse F; Pompiati M; Kollmorgen G; da Silva Mateus Seidl R; Bossenmaier B; Lau W; Schantz C; Stracke JO; Brinkmann U; Onda M; Pastan I; Bosslet K; Niederfellner G
Mol Oncol; 2016 Oct; 10(8):1317-29. PubMed ID: 27507537
[TBL] [Abstract][Full Text] [Related]
38. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.
Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P
Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296
[TBL] [Abstract][Full Text] [Related]
39. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.
Kreitman RJ; Bailon P; Chaudhary VK; FitzGerald DJ; Pastan I
Blood; 1994 Jan; 83(2):426-34. PubMed ID: 8286741
[TBL] [Abstract][Full Text] [Related]
40. Improving the
Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
